Efficacy and safety of serial atorvastatin load in Chinese patients undergoing elective percutaneous coronary intervention: results of the ISCAP (Intensive Statin Therapy for Chinese Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention) randomized controlled trial

doi:10.1093/eurheartj/suv021

CORC > 兰州大学 > 兰州大学 > 第一临床医学院 > 期刊论文

	Efficacy and safety of serial atorvastatin load in Chinese patients undergoing elective percutaneous coronary intervention: results of the ISCAP (Intensive Statin Therapy for Chinese Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention) randomized controlled trial
	Zheng, B; Jiang, J; Liu, HL; Zhang, J; Li, H; Su, X; Wang, HC; Song, ZY; Han, YL; Lei, H
刊名	EUROPEAN HEART JOURNAL SUPPLEMENTS
	2015-03
卷号	17 期号:B 页码:B47-B56
关键词	Atorvastatin Percutaneous coronary intervention Periprocedural myocardial infarction
ISSN号	1520-765X
DOI	10.1093/eurheartj/suv021
文献子类	Article
英文摘要	Although several studies have suggested that intensive statin pretreatment could reduce the incidence of procedure-related myocardial infarction in western population, the data on the effect in Asian patients have been still limited. The aim of the study was to investigate the efficacy and safety of intensive atorvastatin load in Chinese patients undergoing elective PCI. A total of 1202 patients with stable angina or non-ST-segment elevation acute coronary syndrome (NSTE-ACS) scheduled to undergo PCI received either intensive statin treatment (80 mg atorvastatin daily x 2 days before PCI and 40 mg daily x 30 days after PCI) or usual care. The primary endpoint was incidence of major adverse cardiac events (cardiac death, myocardial infarction, or unexpected target vessel revascularization) within 30 days after PCI. Safety endpoints include the incidence of contrast induced nephropathy (CIN), ALT/AST >3 upper limit of normal (ULN), CK >5 ULN. The incidence of 30-day MACE did not significantly differ between the intensive group and control group (19.4 vs 18.3%, P = 0.63). Multivariate analysis revealed age (OR = 1.024, 95% CI 1.003-1.045, P = 0.023) and total stent length as an independent predictor of 30-day MACE (OR = 1.012, 95% CI 1.007-1.018, P < 0.0001). The incidence of CIN was comparable between intensive group and control group (4.09 vs 4.39%, P = 0.795). No significant differences were observed in other safety profile at all follow-ups between treatment groups. The ISCAP trial demonstrated that serial intensive atorvastatin therapy did not improve the clinical outcome with similar safety profile comparing with usual care among Chinese patients undergoing elective PCI.
学科主题	Cardiovascular System & Cardiology
出版地	OXFORD
资助项目	国家科技支撑计划
项目编号	National Key Technology R&D Program in the 12th Five-year Plan of China [2011BAI11B07, 2012ZX093016-002]
语种	英语
WOS记录号	WOS:000357873000004
资助机构	MOST
内容类型	期刊论文
源URL	[http://ir.lzu.edu.cn/handle/262010/178559]
专题	第一临床医学院_期刊论文
通讯作者	Huo, Y (reprint author), Peking Univ, Hosp 1, Dept Cardiol, 8 Xishiku St, Beijing 100034, Peoples R China.
推荐引用方式 GB/T 7714	Zheng, B,Jiang, J,Liu, HL,et al. Efficacy and safety of serial atorvastatin load in Chinese patients undergoing elective percutaneous coronary intervention: results of the ISCAP (Intensive Statin Therapy for Chinese Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention) randomized controlled trial[J]. EUROPEAN HEART JOURNAL SUPPLEMENTS,2015,17(B):B47-B56.
APA	Zheng, B.,Jiang, J.,Liu, HL.,Zhang, J.,Li, H.,...&Huo, Y .(2015).Efficacy and safety of serial atorvastatin load in Chinese patients undergoing elective percutaneous coronary intervention: results of the ISCAP (Intensive Statin Therapy for Chinese Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention) randomized controlled trial.EUROPEAN HEART JOURNAL SUPPLEMENTS,17(B),B47-B56.
MLA	Zheng, B,et al."Efficacy and safety of serial atorvastatin load in Chinese patients undergoing elective percutaneous coronary intervention: results of the ISCAP (Intensive Statin Therapy for Chinese Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention) randomized controlled trial".EUROPEAN HEART JOURNAL SUPPLEMENTS 17.B(2015):B47-B56.